![[Toyota Times] From Strengthening Foundations to Boosting Productivity - Toyota Focuses on Break-Even Volume](https://businessfortnight.com/wp-content/uploads/2025/11/Toyota-Times-From-Strengthening-Foundations-to-Boosting-Productivity-Toyota-218x150.jpg "[Toyota Times] From Strengthening Foundations to Boosting Productivity – Toyota Focuses on Break-Even Volume")
Negma Group has transformed 580 convertible bonds in Oxurion leading to a EUR 1,450,000 capital enhance. This is an element of Negma Group’s EUR 30 million Capital Commitment1 that may permit Oxurion to focus on progressing its novel and differentiated again of the eye drug candidate concentrating on potential market alternatives of over USD 5 billion.
Leuven, BELGIUM, Boston, MA, US – October 28, 2022 – 07.00 PM CET – In accordance with article 15 of the Belgian Act of May 2, 2007 on the disclosure of main participations in issuers of which shares are admitted to buying and selling on a regulated market and concerning miscellaneous provisions, Oxurion NV (Euronext Brussels: OXUR) (the “Company” or “Oxurion”), broadcasts the beneath info, following the issuance of (i) 909,090 new peculiar shares on October 12, 2022, for a complete quantity of EUR 100,000, as the consequence of the conversion of 40 class A convertible bonds, (ii) 4,750,000 new peculiar shares on October 12, 2022, for a complete quantity of EUR 332,500, as the consequence of the conversion of 133 class B convertible bonds, (iii) 5.857.142 new peculiar shares on October 19, 2022, for a complete quantity of EUR 410,000, as the consequence of the conversion of 164 class B convertible bonds, (iv) 5,000,000 new peculiar shares on October 24, 2022, for a complete quantity of EUR 300,000, as the consequence of the conversion of 120 class B convertible bonds, and (v) 6,150,000 new peculiar shares on October 26, 2022, for a complete quantity of EUR 307,500, as the consequence of the conversion of 123 class B convertible bonds, all pursuant to the Capital Commitment entered into with Negma Group.
Following completion of the capital enhance by way of the conversion of the convertible bonds, the complete quantity of shares issued by Oxurion quantities to 77,825,765 excellent peculiar shares carrying voting rights (in comparison with 55,159,533 excellent peculiar shares beforehand). This quantity can be used as the denominator for the calculation of the percentages of shareholdings.
Therefore, Oxurion publishes the following up to date info:
| 72,356,161.32 | |
|
77,825,765 |
|
77,825,765 |
|
|
|
|
END
About Oxurion
Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical firm creating subsequent technology customary of care ophthalmic therapies, that are designed to enhance and higher protect imaginative and prescient in sufferers with retinal issues together with diabetic macular edema (DME), the main trigger of imaginative and prescient loss in working-age folks, in addition to different situations. Oxurion intends to play an essential position in the remedy of retinal issues, together with the profitable growth of THR-149, its novel therapeutic for the remedy of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a possible new customary of look after the as much as 50% of DME sufferers displaying suboptimal response to anti-VEGF remedy. Oxurion is headquartered in Leuven, Belgium, with company operations in Boston, MA. More info is accessible at www.oxurion.com.
Important details about forward-looking statements
Certain statements on this press launch could also be thought of “forward-looking”. Such forward-looking statements are based mostly on present expectations, and, accordingly, entail and are influenced by numerous dangers and uncertainties. The Company due to this fact can’t present any assurance that such forward-looking statements will materialize and doesn’t assume any obligation to replace or revise any forward-looking assertion, whether or not because of this of new info, future occasions, or every other cause. Additional info regarding dangers and uncertainties affecting the business and different elements that might trigger precise outcomes to vary materially from any forward-looking assertion is contained in the Company’s Annual Report. This press launch doesn’t represent a suggestion or invitation for the sale or buy of securities or property of Oxurion in any jurisdiction. No securities of Oxurion could also be provided or offered inside the United States with out registration underneath the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any relevant U.S. state securities legal guidelines.
For additional info please contact:
1 Press launch Oxurion, 06/04/2021 and Press launch Oxurion, 02/09/2022
- OXUR PR_Voting rights (ENG)_20221026
